Status:
COMPLETED
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Lead Sponsor:
Sirion Therapeutics, Inc.
Collaborating Sponsors:
ReVision Therapeutics, Inc.
Conditions:
Geographic Atrophy
Dry Age Related Macular Degeneration
Eligibility:
All Genders
50-89 years
Phase:
PHASE2
Brief Summary
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
Eligibility Criteria
Inclusion
- males or females, 50 to 89 years of age
- must have GA from AMD in one or both eyes
Exclusion
- GA due to any disease other than AMD (eg, drug-induced)
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT00429936
Start Date
December 1 2006
End Date
May 1 2010
Last Update
June 22 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.